Blog
RSS FeedPosted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of secukinumab (Cosentyx) for ankylosing spondylitis
23 August 2016 - CADTH publishes second outcome for Cosentyx this month. ...
Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of Truvada for PrEP
24 August 2016 - The recommendation comes with conditions. ...
Posted by Michael Wonder on 26 Aug 2016
NICE backs non-surgical option for fibroids
26 August 2016 - Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the NHS for ...
Posted by Michael Wonder on 25 Aug 2016
CADTH recommends the reimbursement of secukinumab (Cosentyx) for psoriatic arthritis
23 August 2016 - CADTH has issued a final recommendation on the reimbursement of secukinumab (Cosentyx) for patients with psoriatic ...
Posted by Michael Wonder on 25 Aug 2016
NICE recommends Servier's Lonsurf (trifluridine with tipiracil hydrochloride)
24 August 2016 - New treatment for patients with advanced colorectal cancer. ...
Posted by Michael Wonder on 24 Aug 2016
Amgen provides update on status of Parsabiv (etelcalcetide) new drug application submitted to the U.S. FDA
24 August 2016 - Amgen today announced that the U.S. FDA has issued a complete response letter for the new drug ...
Posted by Michael Wonder on 24 Aug 2016
Teva Canada Innovation announces approval of three-times-a-week Copaxone 40mg/mL by Health Canada
23 August 2016 - Teva Canada Innovation announced today that Health Canada has approved three-times-a-week Copaxone (glatiramer acetate) 40 mg/mL injection. ...
Posted by Michael Wonder on 24 Aug 2016
NICE issues draft guidance on the use of Eylea (afilbercept)
24 August 2016 - NICE has issued draft final guidance on the use of Bayer's Eylea (aflibercept) on the NHS. ...
Posted by Michael Wonder on 24 Aug 2016
NICE approves new cancer drugs for routine NHS use
24 August 2016 - Two cancer treatments, previously only available to patients through the Cancer Drugs Fund, will now be routinely ...
Posted by Michael Wonder on 23 Aug 2016
Rare blood cancer therapy Oncaspar gets NICE green light
23 August 2016 - Treatment from Baxalta/Shire for patients with acute lymphoblastic leukaemia recommended by NICE for use on the ...
Posted by Michael Wonder on 22 Aug 2016
European Commission grants marketing authorization for Gilead’s once-daily Truvada for reducing the risk of sexually acquired HIV-1
22 August 2016 - Truvada is the first anti-retroviral medicine to be licensed in Europe for pre-exposure prophylaxis, in combination with ...
Posted by Michael Wonder on 22 Aug 2016
FDA approves Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules CII with abuse-deterrent properties for the management of pain
19 August 2016 - Pfizer announced today that the U.S. FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release ...
Posted by Michael Wonder on 21 Aug 2016
Insights from the PBAC July 2016 meeting
22 August 2016 - The publication of the outcomes from the PBAC July 2016 meeting presents another opportunity to study ...
Posted by Michael Wonder on 21 Aug 2016
Summary of the outcomes from the PBAC July 2016 meeting
19 August 2016 - The outcomes from the PBAC July 2016 meeting are now in the public domain. ...
Posted by Michael Wonder on 19 Aug 2016
NICE issues draft guidance on the first-line use of sorafenib tosylate (Nexavar) in advanced/metastatic hepatocellular carcinoma
19 August 2016 - The merits of Nexavar in liver cancer have been reviewed by NICE under the CDF rapid reconsideration ...